Read More Pharma Industry News Avidity Biosciences (Nasdaq: RNA) opens access to del-zota in DMD44 as BLA filing nears Avidity Biosciences launches U.S. access program for del-zota in DMD exon 44 patients. See how this ties into FDA submission plans and the Novartis acquisition. byVenkateshNovember 19, 2025